Develops experimental therapies for people with solid tumors, including an antibody designed to bind two targets and drug-carrying antibodies.
10-K for FY2025, filed Feb 26, 2026We are a clinical-stage biotechnology company focused on delivering the next wave of transformative therapies to bring a brighter future…View ↗
CR-002 is an ADC that delivers a topoisomerase toxin to cancer cells that express PD-L1, a cell surface protein that suppresses T-cell…View ↗
We recently announced a partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (“Kelun”), a leading Chinese biotech company…View ↗
The company earns money by licensing internally developed drug candidates. Licensees pay upfront, may owe additional payments when clinical, regulatory or sales milestones occur, and owe royalties on commercial product sales.
10-K for FY2025, filed Feb 26, 2026The Company follows ASC 606, Revenue from Contracts with Customers (“ASC 606”). The Company has earned revenue from licenses of our…View ↗
$10.8M
10-K for FY2025, filed Feb 26, 2026
$10.8M ↗
Revenue came from a China-based customer licensing drug candidates.
10-K for FY2025, filed Feb 26, 2026
No. It lost $153.9M in FY2025.
8-K, filed Jul 15, 2026
On July 14, 2026, Crescent Biopharma, Inc. (“Crescent” or the “Company”) entered into an underwriting agreement (the “Underwriting…View ↗
Growing. Revenue grew 9.4x in 4 years, from $1.2M in FY2021 to $10.8M in FY2025, about 75% a year.
From glycomimetic drugs to antibody therapies
The earlier report focused on glycomimetic drugs for cancer and inflammatory diseases; the latest focuses on antibody therapies and antibody-drug conjugates for solid tumors.
10-K for FY2022, filed Mar 29, 2023 10-K for FY2025, filed Feb 26, 2026We are a late-stage clinical development biotechnology company focused on improving the lives of people living with cancer and inflammatory…View ↗
Competes with Merck, Bristol Myers Squibb, Genentech, AstraZeneca, Summit Therapeutics, BioNTech, LaNova Medicines, 3SBio, Pfizer, Compass Therapeutics, and Henlius
10-K for FY2025, filed Feb 26, 2026There are several approved immuno-oncology biologic therapies for the treatment of solid tumor indications, including, but not limited to…View ↗
Loading...